Physician profile

David M Jutkowitz

Family Medicine · Stratford, CT

NPI 1649209107

$517.92

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$178.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $264.91 2021-2023
Novo Nordisk INC $96.27 2019-2020
Pfizer INC. $65.70 2019-2023
Amneal Pharmaceuticals LLC $34.80 2022-2023 Rytary
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $14.60 2023 Xifaxan
Exact Sciences Corporation $14.35 2023 Cologuard Collection Kit
Idorsia Pharmaceuticals US INC $14.27 2023 Quviviq
Astrazeneca Pharmaceuticals LP $13.02 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David M Jutkowitz

$517.92

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/580759/david-m-jutkowitz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.